Low Tumor Infiltrating Mast Cell Density Reveals Prognostic Benefit in Cervical Carcinoma

Fan Guo, PhD1,*, Wei-Na Kong, MM1,*, De-Wei Li, MM2,*, Gang Zhao, MM3, Hui-Li Wu, MM1, Miyessar Anwar, MM1, Xiao-Qian Shang, MM1, Qian-Nan Sun, MM1, Cai-Ling Ma, PhD4, and Xiu-Min Ma, PhD1

Abstract
Objectives: Research on the role of mast cells (MCs) in cervical tumor immunity is more limited. Therefore, our study aimed to evaluate the prognostic value of MCs and their correlation with the immune microenvironment of cervical carcinoma (CC).

Methods: The Cancer Genome Atlas (TCGA) data was utilized to obtain the degree of immune infiltration of MCs in CC. Meanwhile, this study retrospectively collected patient clinical characteristic data and tissue specimens to further verify the relevant conclusions. Mast cell density (MCD) was measured by the CIBERSORT algorithm in TCGA data and immunohistochemical staining of tryptase in CC tissues. Finally, differentially expressed genes (DEGs) of TCGA data were performed using “limma” packages and key gene modules were identified using the MCODE application in Cytoscape.

Results: The results showed MCs were diffusely distributed in CC tissues. Moreover, we found that low tumor-infiltrating MCD was beneficial for overall survival (OS) in the TCGA cohort. Consistent conclusions were also obtained in a clinical cohort. In addition, a total of 305 DEGs were analyzed between the high tumor-infiltrating MCD and low tumor-infiltrating MCD group. Seven key modules, a total of 34 genes, were screened through the MCODE plug-in, which was mainly related to inflammatory response and immune response and closely correlated with cytokines including CSF2, CCL20, IL1A, IL1B, and CXCL8.

Conclusion: In short, high tumor-infiltration MCs in CC tissue was associated with worse OS in patients. Furthermore, MCs were closely related to cytokines in the tumor microenvironment, suggesting that they collectively played a role in the immune response of the tumor. Therefore, MCD may be a potential prognostic indicator and immunotherapy target of CC.

Keywords
cervical carcinoma, mast cell, CIBERSORT, prognosis, tumor microenvironment

1. Department of Medical Laboratory Center, Tumor Hospital Affiliated to Xinjiang Medical University, State Key Laboratory of Pathogenesis, Prevention and Treatment of High Incidence Diseases in Central Asia, Urumqi, Xinjiang, China
2. Basic Medical College of Xinjiang Medical University, Urumqi, Xinjiang, China
3. Department of Blood Transfusion, Affiliated Traditional Chinese Medicine Hospital of Xinjiang Medical University, Urumqi, Xinjiang, China
4. Department of Gynecology, The First Affiliated Hospital of Xinjiang Medical University, State Key Laboratory of Pathogenesis, Prevention and Treatment of High Incidence Diseases in Central Asia, Urumqi, Xinjiang, China

* These authors contributed equally to this work.

Corresponding Authors:
Cai-Ling Ma, Department of Gynecology, The First Affiliated Hospital of Xinjiang Medical University, State Key Laboratory of Pathogenesis, Prevention and Treatment of High Incidence Diseases in Central Asia, 137 Le Yu Shan South Road, Urumqi, Xinjiang 830054, China. Email: hymcl3009661999@126.com
Xiu-Min Ma, Department of Medical Laboratory Center, Tumor Hospital Affiliated to Xinjiang Medical University, State Key Laboratory of Pathogenesis, Prevention and Treatment of High Incidence Diseases in Central Asia, No. 789 Suzhou Road, Urumqi, Xinjiang 830000, China. Email: maximumin1210@sohu.com

Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage).
**Abbreviations**

MC, mast cell; CC, cervical carcinoma; TCGA, The Cancer Genome Atlas; MCD, mast cell density; DEGs, differentially expressed genes; OS, overall survival; ROC, receiver operating characteristic curve; TME, tumor microenvironment; FIGO, International Federation of Gynecology and Obstetrics; IHC, immunohistochemistry; GO, Gene Ontology; PPI, protein–protein interaction network; BP, biological process; NF-kB, nuclear factor kB; VEGF, vascular endothelial growth factor; FGF-2, fibroblast growth factor; MMP, matrix metalloproteinases; MUCs, mucins.

Received: November 29, 2021; Revised: April 21, 2022; Accepted: May 23, 2022.

**Introduction**

Death due to cancers is a growing threat to human survival.1 Cervical carcinoma (CC) is one of the leading causes of cancer death in women. Globally, CC accounts for almost 12% of all female cancers, making it the fourth most common female cancer in the world.2,3 According to the 2018 Global Cancer Statistics report, the incidence and mortality of CC accounted for 6.6% and 7.5% of all female cancer patients, respectively.4 As a highly heterogeneous disease, tumor microenvironment (TME) plays an important role in the occurrence, development, and prognosis of CC. Normal TME plays a central role in maintaining tissue homeostasis and serves as a barrier to tumorigenesis, while abnormal TME plays an opposite role.5 Tumor-infiltrating immune cells, as an important component of TME, play a promote or anti-tumor function by influencing the host immune status and biological behavior.6 Therefore, a better understanding of the TME is beneficial to the management of CC.

Mast cells (MCs), as innate immune cells, have been generally recognized for their roles in allergy and inflammation.7 MCs are widely distributed in all tissues and are highly pluripotent cells that secrete numerous vasoactive and pro-inflammatory mediators,8 proteases, cytokines, and chemokines.7 However, the function of MCs in regulating TME has remained largely unknown.

As a source of pro-tumor and anti-tumor factors, MCs have dual roles in tumors, while in rare cases, they may be simple indolent bystanders.9 On the one hand, in some tumors, MCs are always favorable for tumor development and are significantly associated with poor prognosis;10,11 on the other hand, in some tumors, MCs always seem to exert anti-tumor effects and confer a survival advantage.12 In CC, several studies have investigated the relationship between MCs and development with conflicting conclusions. Graham et al reported that the number of MCs decreased with tumor progression,13 whereas Benitez-Bribesca et al, Wilkins et al, and Ferrandina et al supported that MCs infiltration increased with cancer development and was often associated with worse prognosis.14–17 Therefore, studies that can reveal the relationship between mast cell density (MCD) and CC prognosis are urgently needed.

Here, we performed an immune infiltration study on The Cancer Genome Atlas (TCGA) cohort using the CIBERSORT algorithm. Meanwhile, the prognostic relationship between MCD and CC patients was also evaluated by collecting clinicopathological data and immunohistochemical staining of tissue specimens with MCs tryptase. Subsequently, differentially expressed genes (DEGs) analysis was conducted on TCGA data through the “limma” package in R software. Finally, the MCODE plug-in in Cytoscape software was utilized to explore DEGs to observe the relationship between MCs and key genes. In brief, this study reduced the controversy of MCs in CC, suggesting that MCD was a potential prognostic biomarker and therapeutic target in CC.

**Materials and Methods**

**TCGA Cohort Acquisition**

The transcriptome profiling data of 253 patients with cervical squamous cell carcinoma were obtained from the TCGA database (https://portal.gdc.cancer.gov/cart). We finally analyzed the cases of 222 patients through sorting. Moreover, when we acquired the mRNA data of CC patients, duplicate values were deleted, and the “limma” package in R software was used to correct it into the corresponding input file. TCGA, as a publicly published database, requires neither the ethics committee’s approval nor the patient’s informed consent to obtain information.

**CIBERSORT**

CIBERSORT is an algorithm based on support vector machine regression that can calculate the cell composition of the tissue from the gene expression profile using the deconvolution method.18 In our study, CIBERSORT was applied to TCGA data to obtain the estimated proportion of immune cell types in each tumor sample by using LM22, which was regarded as a reference expression signature for 100 permutations.

**Clinical Patients Data Collection**

Clinical data and paraffin specimens of CC patients who underwent radical primary tumor resections without prior treatment in Xinjiang Medical University Affiliated Tumor Hospital (Xinjiang, China) were collected retrospectively. Cases that received chemotherapy or radiotherapy before surgery and had autoimmune diseases were excluded. After excluding patients with incomplete information, 43 patients were eventually involved. All the cases of the study were confirmed to be CC by surgery and pathology. And the cancer was staged
according to the recommendations of the International Federation of Obstetrics and Gynecology (FIGO).

**Immunohistochemistry**

Formalin-fixed paraffin-embedded surgical specimens were used for the immunohistochemistry (IHC) study. The main steps of IHC were as follows: section drying, xylene dewaxing, graded alcohol hydration, phosphate buffered saline washing, antigen retrieval (microwave oven for 15 min), endogenous peroxidase inactivation, goat serum blocking, primary antibody overnight, secondary antibody incubation, diaminobenzidine staining, hematoxylin counterstaining, etc. The primary antibody was composed of rabbit anti-human polyclonal mast cell tryptase (diluted 1:100, Beijing Boiynthesis Biotechnology Co). Positive staining was assessed by computer-aided image analysis and Image J software. The evaluation of MC infiltration and density was determined from 3 random areas by 2 independent pathologists who were blinded to the pathology and clinical status of the patients.

**Differentially Expressed Genes Analysis**

R software (version 4.1.1) was utilized to standardize data preprocessing and ID conversion. DEGs analysis on microarray data from the TCGA repository was screened by the “Limma” package. At least a 2-fold change was set and the adjusted \(p\)-value was .05. The results were visualized as a volcano plot and a heat map using “ggplot2” and “Pheatmap” packages of R software. Besides, Uniprot, a website (https://www.uniprot.org/) that can provide the comprehensive and high-quality resource of freely accessible protein sequence and functional information, was used for the unified standardization of DEGs.

**Protein–Protein Interaction Network Creation**

We analyzed the protein–protein interaction (PPI) of DEGs via STRING (http://string-db.org/) online database. The interaction with a combined score > 0.7 was selected as significant. An interactive network of component-target was visualized by Cytoscape software (version 3.7.1). Furthermore, MCODE, a density-based nonoverlapping clustering algorithm plug-in of Cytoscape software, was performed to establish a PPI network for identifying key gene modules. The scoring parameters for cluster analysis followed the default parameters of the application.

**Gene Ontology Analysis**

DAVID 6.8 (https://david.ncifcrf.gov/home.jsp) is the website that can clarify the biological functions of genes. We performed gene ontology (GO) pathway enrichment analysis. \(P\)-value <.05 was considered to be statistically different.

**Correlation Analysis Between MCs and MCODE Module of Genes**

The correlation between MCs and key gene modules obtained from the MCODE plug-in was further learned to determine potential functions. Use the “circize” package in R to perform the correlation analysis on the top 2 gene-rich clusters. Furthermore, in R software, the package of “ggcorrplot” and “ggthemes” was utilized to analyze the relationship between MCs infiltration and gene-rich clusters.

**Statistical Analysis**

All statistical analyses were performed using IBM SPSS Statistics (version 26.0), GraphPad Prism (version 8.0.1), and R software (version 4.1.1). A two-sided \(P<.05\) was regarded as statistically significant. Cutoff values for the MCs were calculated by receiver operating characteristic curve (ROC) analysis for grouping. Kaplan-Meier analysis and the Log-rank test were used to evaluate the relationship between MCD and overall survival (OS). Pearson’s chi-square test or Fisher’s exact test was used to assess the association between clinicopathological features and MCD.

**Results**

**Relationship Between MCD and Clinical Characteristics of CC Patients**

CIBERSORT algorithm was used to obtain the composition of 22 kinds of immune cells in the TCGA cohort of CC (n = 222) (Supplemental Table 1). It can be intuitively seen that macrophages and T cells accounted for the main part (Supplemental Figure 1). We then integrated 22 types of immune cells with patient clinical data to explore implications for patient outcomes. In short, MCs, CD4T cells, and NK cells were associated with statistically significant prognosis in CC patients (all \(P<.05\), Supplemental Table 2).

To be more specific, Kaplan-Meier survival analyses and Log-rank tests were utilized to evaluate the prognostic value of MCD in CC. It was found that high tumor-infiltrating MCD was related to the poor prognosis of the patients (\(p = .0003\), Figure 1A). We further carried out validation in a clinical patient. In the clinical patient cohort, we also gained a negative relationship between MCD and patient prognosis (\(p = .0475\), Figure 1B). Cutoff value was set at 12.42% to define the high and low tumor-infiltrating MCs (Supplemental Table 3). A total of 43 CC patients were included in this study. Detailed descriptions of patients’ demographic and clinicopathological characteristics were shown in Table 1. By using immunohistochemical staining of tryptase to identify MCs, MCs were dispersed in tumor tissues at different densities (Figure 2). Subsequently, the relationship between MCD and clinical features was accessed (Figure 3, Supplemental Table 3). Except for age (\(p = .008\)), other clinical variables were not related to the tumor-infiltrating MCs in CC tissue.
Identification of DEGs of TCGA Data

By performing DEGs analysis on the microarray data of TCGA using the “limma” package, we identified numerous genes that were up-regulated or down-regulated between high and low tumor-infiltrating MCD groups. We got 305 DEGs in total (Table 2), of which 278 genes were up-regulated and 27 genes were down-regulated. The volcano graph showed that significantly DEGs involved MUC6 and MUC5AC, as well as focused on several important cytokines and chemokines including CSF2, IL-1A, IL-1B, CXCL8, CCL20, etc (Figure 4).

PPI Analysis of DEGs

The DEGs between high tumor-infiltrating and low tumor-infiltrating MCD were submitted to the STRING online database, acquiring a PPI network consisting of 300 nodes and 164 edges. The results were visualized through Cytoscape software (Figure 5A). Furthermore, we also conducted MCODE analysis on DEGs, established PPI networks, and obtained 7 key gene modules, a total of 34 key genes (Table 3). To learn more about the potential biological mechanism related to the network, we screened the top 2 gene clusters with the highest clustering score (Figure 5B and C).

Functional Enrichment Analysis of the First 2 Key Gene Modules

Functional enrichment of the first 2 key gene modules was performed using DAVID 6.8. Biological process (BP) became the focus in GO functional enrichment analysis. The results showed that they were mainly related to inflammatory response and the immune response (Table 4).

Correlation Analysis

There was a certain intensity of association between the genes of the top 2 gene enrichment groups, principally focusing on MUC6 and MUC13. MUC6 was primarily related to CSF2, CXCL8, and IL1B. MUC13 was mainly associated with CSF2, CXCL8, and CCL20 (Figure 6A). In addition, the correlation coefficient and p-value were also obtained (Figure 6B, Supplemental Table 4). The results showed that MCs were moderately associated with CXCL8 (P=0, Cor=0.57), IL1A (P=0, Cor=0.56), and IL1B (P=0, Cor=0.6), were low correlated with CSF2 (P=0, Cor=0.36), and CCL20 (P=0, Cor=0.39) compared to other genes. Taken together, MCs may interact with cytokines in the TME, which lead to a combined effect in tumor progression.

Table 1. Clinical Characteristics of 43 Patients With Cervical Carcinoma.

| Parameter                        | N (%) or mean (s.d.) |
|----------------------------------|----------------------|
| Total number of patients enrolled| 43                   |
| Age at first diagnosis (years)   |                      |
| ≤58                              | 32 (74.4%)           |
| >58                              | 11 (25.6%)           |
| Ethnicity                        |                      |
| Han                              | 24 (55.8%)           |
| Others                           | 19 (44.2%)           |
| Differentiation                  |                      |
| Poor                             | 9 (20.9%)            |
| Middle/High                      | 34 (79.1%)           |
| Tumor size                       |                      |
| ≤4 cm                            | 31 (72.1%)           |
| >4 cm                            | 12 (27.9%)           |
| Lymph node metastasis            |                      |
| No                               | 31 (72.1%)           |
| Yes                              | 12 (27.9%)           |
| FIGO stage                       |                      |
| IA ~ IIA2                        | 37 (86.0%)           |
| ≥IIB                             | 6 (14.0%)            |
| MCD                              |                      |
| Low                              | 31 (72.1%)           |
| High                             | 12 (27.9%)           |

Figure 1. Kaplan-Meier analysis of overall survival in patients with cervical carcinoma. The results showed that the high tumor-infiltrating MCD group was associated with a worse prognosis for the patients. TCGA cohort (n = 222, P = .0003) (A). Clinical patient cohort (n = 43, P = .0475) (B).

Figure 4. Volcano plot of DEGs comparing high and low tumor-infiltrating MCD. The volcano plot shows that DEGs were significantly enriched between high and low tumor-infiltrating MCD. The red spots represent up-regulated genes and the green spots indicate down-regulated genes. MUC6 and MUC5AC were identified as significantly DEGs.
Discussion

Even with the improvement of early screening and diagnosis of CC, it is still one of the diseases threatening female health. The role of MCs in allergic and inflammatory responses has long been identified and well described.\textsuperscript{21,22} In recent years, with the increasing research on MCs in cancer, its biological functions and mechanisms of action have been continuously revealed. However, studies on MCs and the prognosis of different cancers have reached different conclusions.\textsuperscript{23–25} Similarly, previous studies also observed the anti- and pro-tumor effects of MCs in CC.\textsuperscript{13–17} Our study aimed to explore and clarify this question.

MCs were inflammatory mediators that tended to congregate in the tumor periphery. The number of tumor-infiltrating MCs was related to increased microvessel density in the tumor, enhanced tumor growth and invasion, and poor clinical prognosis.\textsuperscript{26,27} MCs release molecules like vascular endothelial growth factor (VEGF), tryptase, fibroblast growth factor (FGF-2), which can initiate tumor angiogenesis, and molecules like matrix metalloproteinases (MMP-9 and MMP-2) which can enable tumor niche remodeling, migration and invasiveness collectively resulting in cancer progression.\textsuperscript{24} However, there is still controversy on the density of MC and the prognosis of CC patients. Here, externally published TCGA data was utilized to evaluate the prognostic value of MCs infiltration. The results showed that high tumor-infiltrating MCD was associated with worse OS. Furthermore, the conclusion was also verified in a clinical patient cohort. It was concluded that MCs were diffusely distributed in CC tissue using IHC, which suggested that MCD was involved in the development of CC. These
conclusions all suggested that MCs were potential biomarkers for the prognosis of CC.

Subsequently, we screened a total of 305 DEGs between the high tumor-infiltrating MCD and low tumor-infiltrating MCD group, of which 278 were up-regulated genes and 27 were down-regulated genes. STRING online database and Cytoscape software were used to construct a PPI network map of DEGs, and 34 key genes were screened through the

Table 2. The Common DEGs Included 278 Upregulated and 27 Downregulated Genes.

| DEGs | Genes |
|------|-------|
| Upregulated | TTR, PON1, TSPAN8, UGT2B11, ITIH1, UBE2U, SPATA21, SLC22A7, CEACAM16, ANKFN1, PAX2, PLA2G2A, CFHR4, DMRTB1, CSAG2, SST, FOLR1, SOX1, HS3ST4, CSAG3, NTS, CDH12, MT4, ADH1C, HTR2C, PIGR, AADACL2, FRRS1L, GPR12, UGT2B4, ALB, ZB0X, SLC18A3, PCDHB1, RPRM, MAGEA6, C5orf49, CTAG2, KLHL34, FABP1, SPINK13, KRT24, DYNAP, PPP1R14D, INS6, ORM2, ITL1N, GJB1, MRGPRE, PRAP1, KRT77, MAGEA10, IGFL5, KRT3, FGA, NTSR2, SGB1D2, GNAT3, HSD3B1, CLEC2L, MAGEA12, AR, SRARP, CCKBR, SULT1C2, PRSS56, APOH, TRIM43, CNJN18, FAME96C, TCEAL2, FAM228A, KLHL14, ELF5, CCL15, PIWIL2, CNGA3, USH1C, DRG2, NMU01, OADM, MAATS1, SIGLEC8, AMBN, CYP2F1, KNG1, PMP2, PENK, ALPI, TCHH, NO4L, KIR3DL2, C4BP1, ZIC1, KRTAP3-1, COL9A1, B3GAT1, UKP1B, SGB2A2, CRISP2, BRIP2, FOXI2, TMEM72, WFDC6, CD8B, SERPIN12, ECEL1, GSTA3, MUC5B, SLC6A20, EPS18L3, DIRAS2, PTH2R, TLX1, ASTN1, IGF1, STAT1, CSAG1, FDSCP, F11, OTC, SNTN, MAGEA3, SLC01B1, FXYD4, PIWIL1, DPP10, MYH6, CRABP1, PRAC2, DEFA5, MTRNR2L1, SCUBE1, C20orf85, GPR50, MKRN3, DEFA6, HAND1, APOA5, KCNJ16, BMP5, TXO3, FABP4, INS4, GABRG3, LHFPL4, XAGE2, TKTL1, AL583836.1, CCDC33, MAGEC2, ANKS4B, CHAT, CGA, C4BP, TESC, NOBOX, SMIM31, OTX2, SYT5, FGF4, UGT2A1, LYPD8, CLDN8, SLC7A3, MUC5AC, CCDC190, C1orf82, ORM1, PAH, EDN3, ZNF492, CDX2, CTNNB2, SLC9A1, MOGAT2, C6, PLA2G2D, HSPB3, C19orf81, KCNB2, Cxorf67, SPATA19, C6orf10, GMNC, CALCA, PCK1, MUC6, GC, STXBP6, CYP2C9, LRRRC3B, AQP4, MAPK4, SYCE1, MAGEA2, PPP1R1B, GATA4, VIPR2, MIA, SLC01B3, FAM216B, SOX14, HEpacAM2, PKDCC, DDB2, ALDH1A1, HGD, TCRG1IL, HMX1, AFM, POU5F1, MYOD1, EPHA7, MORN5, UGT1A9, TRIM72, CAPN8, SH3GL2, LIX1, KRT28, SLC28A2, MAGEC1, NRAP, UGT1A10, C7orf77, ASC1L1, PCP4, H5S31T, ALP, KRT2, LRRM1, SLITRK5, SYT4, PNLPR3, DACH2, SULT2A1, CA8, KIF1A, ETNPD1, PLD5, VIM, KRT79, SHH, SAGE1, FAM81B, UGT2A3, RNF182, PCDHB2, TMEM179, MUC13, SGB2A1, DDIT4L, APOA2, SLC9C2, PAK5, RNF186, REG1A, SERPIN4, TRIM71, CHRDN, CCDC198, STAC2, TCF23, MAGEB17, DRC1, OR3A2, KCNK9, KRT36, MAGEA1, OR7D2, TCHH1, CFTR, TMEM229A, CTS5, FOXXN4, OR2T8, CCL20, HMGA2, IL1A, SLITRK6, CSF2, NPH2, LRRN4, KRTAP2-3, NX2-2, IL1B, FAM163A, PLP1R5, MPP3, PDPN, PSG6, FAM71A, MMP10, NPY, HRH2, HAS2, FGF5, TFF1, CXL8, CGB8, CDH4, MMP |

Figure 4. Differentially expressed genes analysis of TCGA data. 305 DEGs were obtained in total, of which 278 genes were up-regulated and 27 genes were down-regulated. Volcano graph (A). A heat map of the top 50 DEGs (B).
MCODE plug-in. One of the first 2 key gene modules were some members of the mucins (MUCs) family. MUCs constituted a family of glycoproteins expressed by epithelial cells, and the expression of MUC changed with tumor progression in a variety of cancers. Recent studies have shown that the increase of MUC13 was strongly associated with increased tumor grade and poor prognosis in carcinoma. On the one hand, MUC13 promoted the activation of the nuclear factor κB (NF-κB) signaling resulting in the activation of downstream target genes, thereby facilitating cancer cell proliferation and

Table 3. Results for 7 Key Gene Clusters.

| Cluster | Score (Density*#Nodes) | Nodes | Edges | Node IDs |
|---------|-------------------------|-------|-------|----------|
| 1       | 6.167                   | 13    | 37    | IL1B, ORM1, TTR, IL1A, CCL20, APOH, ALB, APOA2, FGA, ORM2, CXCL8, CSF2, FABP1 |
| 2       | 4                       | 4     | 6     | MUC6, MUC5B, MUC13, MUC5AC |
| 3       | 4                       | 4     | 6     | MAGEA6, CSA1, MAGEA12, MAGEA3 |
| 4       | 4                       | 4     | 6     | NTS, CALCA, NPY, SST |
| 5       | 3                       | 3     | 3     | MAGEC2, MAGEC1, SAGE1 |
| 6       | 3                       | 3     | 3     | MYH6, GATA4, MYOD1 |
| 7       | 3                       | 3     | 3     | CGB8, CGA, CGB5 |
blocking apoptosis. On the other hand, overexpression of MUC13 can lead to tumor progression by regulating human epidermal growth factor receptor 2 (HER2) receptor tyrosine kinase activity. MUC5AC and MUC6, as secreted gel-forming mucins, have been shown to have tumor-promoting effects in several malignant tumors, and high expression of MUC5AC and MUC6 in tumor tissue was significantly associated with poor survival. In addition, MUC5AC was associated with epithelial-mesenchymal transition. The interaction of MUC5AC with integrin β4 led to the activation of focal adhesion kinase (FAK) at Y397, which further promoted tumor metastasis. Finally, for MUC5B, its down-regulation may profoundly alter the proliferation, migration, and invasion of cancer cells through the Wnt/β-catenin pathway. In our study, MUC13, MUC5AC, MUC6, and MUC5B in the MUC family were the key genes screened out. These genes have always been shown to promote tumorigenesis and progression of cancer. However, we did not thoroughly study their mechanism of action in CC in this paper. Whether MUC13, MUC5AC, MUC6, and MUC5B also show negative effects in CC needs to be clarified and verified in future studies.

The first 2 key gene modules were not only related to the MUCs family but also connected with cytokines, which were primarily involved in inflammation and immune responses. And through further correlation analysis, it was found that MCs had a certain correlation with CSF2, CCL20, IL1B, IL1A, and CXCL8 in the key gene module. Lee et al and Xu et al reported that the overexpression of CSF2 was implicated with advanced tumor status, more aggressive clinical course, and worse prognosis in cancer. In fact, MCs can produce and release CSF2 factor to promote tumor growth. The expression level of CCL20 in the CC tissues was significantly higher than in nontumor tissues and normal control tissues, and was correlated with advancing the FIGO stage. It can also exert its effect by recruiting T Helper 17 Cells (Th17), an independent T-cell subset with protumorigenic properties, in the cervical TME. This suggested that MCs were involved in tumorigenesis and progression of tumors in TME.

| MCODE    | GO          | Description                                                                 | Log10 (P)   |
|-----------|-------------|------------------------------------------------------------------------------|-------------|
| MCODE-1   | GO:0002576  | Platelet degranulation                                                       | 6.36×10^-7  |
| MCODE-1   | GO:0006954  | Inflammatory response                                                        | 1.10×10^-4  |
| MCODE-1   | GO:0006955  | Immune response                                                              | 1.64×10^-4  |
| MCODE-1   | GO:2001240  | Negative regulation of extrinsic apoptotic signaling pathway in absence of ligand| 3.07×10^-4  |
| MCODE-1   | GO:0030593  | Neutrophil chemotaxis                                                        | 9.80×10^-4  |
| MCODE-2   | GO:0016266  | O-glycan processing                                                          | 4.34×10^-8  |
| MCODE-2   | GO:0030277  | Maintenance of gastrointestinal epithelium                                   | 2.14×10^-3  |

**Table 4.** Enrichment Analysis of the Top 2 MCODE Genes Function.

**Figure 6.** Correlation between mast cells and the top 2 gene enrichment modules. Mast cells were significantly correlated with CXCL8, IL1A, IL1B, CSF2, and CCL20. Comparison between the first 2 gene enrichment modules (A). Correlation analysis between mast cells and genes or among genes. The circles shown in the figure were all statistically significant, while the nonstatistically significant correlations were hidden. The values in the circles represented correlation coefficients (B).
together with other well-known immune cells and cytokines. This provided new insights on immunotherapy for CC.

In addition, IL1A and IL1B were 2 distinct genes encoding IL-1α and IL-1β, respectively, which served as pro-inflammatory factors. The role of IL-1α and IL-1β has been validated in tumorogenesis, tumor invasiveness, and metastasis. Meanwhile, IL-1α, as an important molecular marker for prognosis, was also an independent predictor of OS in CC patients. IL-1β reduced apoptosis mainly by altering B-cell lymphoma-2/BCL2-Associated X (BCL-2/BAX) protein ratio and increasing p53 mutation, contributing to the development and progression of CC. Moreover, studies have shown that CXCL8 expression was increased in CC and cell lines compared to normal cervical tissue and cervical epithelial cell lines. There was also significant correlation with clinical stage, histological grade, and distant metastasis. And high CXCL8 expression was an independent poor prognostic parameter for CC patients.

Our study suggested that MCs were positively associated with IL1A, IL1B, and CXCL8. Therefore, it is not difficult to deduce that high tumor-infiltrating MCs and these cytokines can produce the same poor clinical prognosis.

Eventually, it is worth mentioning that previous studies have shown that MCs play an indelible role in tumor therapy. There was a potential to suppress neo-vascularization through decreasing MC degranulation and reducing MC numbers, leading to a delay in the tumor growth. It has already proved to be a rational and effective additional therapeutic strategy for tumors negatively affected by MCs. But there are still some limitations that cannot be ignored. The current nanomedicine was a boon to patients in cancer diagnosis and targeted drug delivery. Based on the results of this study, we look forward to the synergistic effect of MCs and cytokines in TME on targeted therapy through nanotechnology in future work.

This study comprehensively analyzed the prognosis of MCs in CC patients through the TCGA dataset, which was verified in a clinical cohort. However, there continue to be some deficiencies in our study. First of all, this study was mainly based on bioinformatics analysis of the public database. Although it was validated in a clinical cohort, our study was small and retrospective research, and should be validated reliability in a prospective cohort with larger sample size. Second, since this study only verified the expression of MCs, the expression of more core genes needed to be further verified in experiments. Meanwhile, further experiments in vitro and in vivo will be carried out to reveal the potential mechanism of MCs in TME. Third, more attention should be paid to the therapeutic effect of MCs on CC in future studies. This study ignored the effect of high and low tumor-infiltrating MCs on therapy. So we cannot know anymore whether the number of MCs affected the treatment modality and the choice of therapeutic drugs to affect the patient’s condition.

**Conclusion**

In summary, we performed a comprehensive analysis of MCs through clinical data and TCGA public data. Low tumor-infiltration MCs in CC tissues was beneficial for OS in patients. Furthermore, MCs were closely related to CSF2, CCL20, IL1A, IL1B, and CXCL8, suggesting that they collectively played a role in the immune response of cervical TME. Therefore, MCD may be a potential prognostic indicator and immunotherapy target for CC. We just hope the results of this study can provide new ideas for prognostic detection and treatment of CC in the future.

**Acknowledgments**

Thanks to the First Affiliated Hospital and Third Affiliated Hospital of Xinjiang Medical University for helping authors in literature review. And we sincerely thank all the authors and study participants for their support in this study.

**Author Contributions**

F.G., W.-N.K., and D.-W.L. have contributed equally to this work. F.G., W.-N.K., and D.-W.L are responsible for conception of the research and preparation of the manuscript. G.Z., H.-L.W., and M.A. are responsible for interpretation and analysis of data. X.-Q.S. and Q.-N.S. are responsible for preparation of the manuscript. C.-L.M. and X.-M.M. are responsible for supervision this manuscript and revision for important intellectual content. All authors read and approved the submitted version.

**Ethics Statement**

This work has been approved by the Ethics Committee of the Tumor Hospital of Xinjiang Medical University (ethical approval number: K-2020013). All patients in the study obtained informed consent or alternative consent.

**Data Availability**

All data generated or analyzed during this study are included in this article.

**Declaration of Conflicting Interests**

The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

**Funding**

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was supported by grants from State Key Laboratory of Pathogenesis, Prevention and Treatment of High Incidence Diseases in Central Asia (SKL-HIDCA-2021-14), the Postdoctoral Fund of Tumor Hospital Affiliated to Xinjiang Medical University, the talent support project of Tumor Hospital Affiliated to Xinjiang Medical University (2021KX002), the Rural Revitalization Project of Young Scientific and technological talents from Xinjiang Uygur Autonomous region (XJWJ-XCZX202210), the National Natural Science Foundation of China (81860528), the Natural Science Foundation of Xinjiang Uygur Autonomous region (2021D01C402), and the science and technology support project from Xinjiang Uygur Autonomous region (2020E0280).

**Supplemental Material**

Supplemental material for this article is available online.
References

1. Roth GA, Abate D, Abate KH, et al. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the global burden of disease study 2017. Lancet. 2018;392(10159):1736-1788.

2. Naga Ch P, Gurram L, Chopra S, Mahantshetty U. The management of locally advanced cervical cancer. Curr Opin Oncol. 2018;30(5):323-329.

3. Di J, Rutherford S, Chu C. Review of the cervical cancer burden and population-based cervical cancer screening in China. Asian Pacific J Cancer Prev. 2015;16(17):7401-7407.

4. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA. Cancer J Clin. 2018;68(6):394-424.

5. Bissell MJ, Hines WC. Why don’t we get more cancer? A proposed role of the microenvironment in restraining cancer progression. Nat Med. 2011;17(3):320-329.

6. Wang J, Li Z, Gao A, Wen Q, Sun Y. The prognostic landscape of tumor-infiltrating immune cells in cervical cancer. Biomed Pharmacother. 2019;120:104944. doi:10.1016/j.biopha.2019.104944.

7. Theoharides TC, Valent P, Akin C. Mast cells, mastocytosis, and related disorders. N Engl J Med. 2015;373(2):163-172.

8. Theoharides TC, Alysandratos KD, Angelidou A, et al. Mast cells and inflammation. Biochim Biophys Acta. 2012;1822(1):21-33.

9. Varricchi G, Guldiero MR, Loffredo S, et al. Are mast cells MASTers in cancer? Front Immunol. 2017;8:424. doi:10.3389/fimmu.2017.00424.

10. Visciano C, Liotti F, Prevete N, et al. Mast cells induce epithelial-to-mesenchymal transition and stem cell features in human thyroid cancer cells through an IL-8-Akt-Slug pathway. Oncogene. 2015;34(40):5175-5186.

11. Sammarco G, Varricchi G, Ferraro V, et al. Mast cells, angiogenesis and lymphangiogenesis in human gastric cancer. Int J Mol Sci. 2019;20(9):2106.

12. Glajcar A, Szpor J, Pacek A, et al. The relationship between breast cancer molecular subtypes and mast cell populations in tumor microenvironment. Virchows Arch. 2017;470(5):505-515.

13. Graham RM, Graham JB. Mast cells and cancer of the cervix. Surg Gynecol Obstet. 1966;123(3):3-9.

14. Ferrandina G, Lainóla L, Zannoni GF, et al. Expression of cyclooxygenase-2 (COX-2) in tumour and stroma compartment in cervical cancer: clinical implications. Br J Cancer. 2002;87(10):1145-1152.

15. Ferrandina G, Ranelli F, Legge F, et al. Prognostic role of the ratio between cyclooxygenase-2 in tumour and stroma compartments in cervical cancer. Clin Cancer Res. 2004;10(9):3117-3123.

16. Benitez-Bribiesca L, Wong A, Utzra D, Castellanos E. The role of mast cell tryptase in neoangiogenesis of premalignant and malignant lesions of the uterine cervix. J Histocom Immunol. 2001;49(8):1061-1062.

17. Wilk M, Liszka L, Paleń P, Gabriel A, Lauďański P. Intensity of angiogenesis and mast cell infiltration in cervical intraepithelial and invasive lesions – are they correlated? Pathol Res Pract. 2010;206(4):217-222.

18. Chen B, Khodadoust MS, Liu CL, Newman AM, Alizadeh AA. Profiling tumor infiltrating immune cells with CIBERSORT. Methods Mol Biol. 2018;1711:243-259. doi:10.1007/978-1-4939-7493-1_12.

19. Ritchie ME, Phipson B, Wu D, et al. Limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43(7):e47.

20. Huang da W, Sherman BT, Zheng X, et al. Extracting biological meaning from large gene lists with DAVID. Curr Protein Bioinform. 2009;13;13.11. doi: 10.1002/0471250953.bi1311s27.

21. Xu H, Bin NR, Sugita S. Diverse exocytic pathways for mast cell mediators. Biochem Soc Trans. 2018;46(2):235-247.

22. Piliponsky AM, Acharya M, Shubin NJ. Mast cells in viral, bacterial, and fungal infection immunity. Int J Mol Sci. 2019;20(12):2851.

23. Mao Y, Feng Q, Zheng P, et al. Low tumor infiltrating mast cell density confers prognostic benefit and reflects immunomodulation in colorectal cancer. Int J Cancer. 2018;143(9):2271-2280.

24. Ribatti D, Drivellosi E. Mast cells, angiogenesis, and tumour growth. Biochim Biophys Acta – Mol Basis Dis. 2012;1822(1):2-8.

25. Liu H, Yang Y. Identification of mast cell-based molecular subtypes and a predictive signature in clear cell renal cell carcinoma. Front Mol Biosci. 2021;8(9):1-15.

26. Mehtani D, Puri N. Steering mast cells or their mediators as a prospective novel therapeutic approach for the treatment of hematological malignancies. Front Oncol. 2021;11:731323. doi:10.3389/fonc.2021.731323.

27. Ribatti D. Mast cells as therapeutic target in cancer. Eur J Pharmacol. 2016;778:152-157. doi:10.1016/j.ejphar.2015.02.056.

28. Wang J, El-Bahrawy M. Expression profile of mucins (MUC1, MUC2, MUC5AC, and MUC6) in ovarian mucinous tumours: expression of mucins (MUC1, MUC2, MUC5AC, and MUC6) in ovarian mucinous tumours: changes in expression from benign to malignant tumours. Histopathology. 2015;66(4):529-535.

29. Sheng Y, Ng CP, Laurie R, et al. MUC13 Overexpression in renal cell carcinoma plays a central role in tumor progression and drug resistance. Int J Cancer. 2017;140(10):2351-2363.

30. Xu Z, Liu Y, Yang Y, et al. High expression of Mucin13 associates with grimmer postoperative prognosis of patients with non-metastatic clear-cell renal cell carcinoma. Oncotarget. 2017;8(5):7548-7558.

31. Düvel K, Yecies JL, Menon S, et al. Activation of a metabolic gene regulatory network downstream of mTOR complex 1. Mol Cell. 2010;39(2):171-183.

32. Marinucchini S, Rauth S, Ganguly K, Zhang C, Ponnusamy MP. Mucins reprogram stemness, metabolism and promote chemoresistance during cancer progression. Cancer Metastasis Rev. 2021;40(2):575-588.

33. Lakshmanan I, Rachagani S, Hauke R, et al. MUC5AC Interactions with integrin β4 enhances the migration of lung cancer cells through FAK signaling. Oncogene. 2016;35(31):4112-4121.

34. Wang S, You L, Dai M, Zhao Y. Mucins in pancreatic cancer: a well-established but promising family for diagnosis, prognosis and therapy. J Cell Mol Med. 2020;24(18):10279-10289.
35. Betge J, Schneider NI, Harbaum L, et al. Associations between the expression of mucins (MUC1, MUC2, MUC5AC and MUC6) and clinicopathologic parameters of human breast carcinomas. *Indian J Pathol Microbiol.* 2020;63(4): 551-558.

36. Lahdaoui F, Messager M, Vincent A, et al. Depletion of MUC5B mucin in gastrointestinal cancer cells alters their tumorigenic properties: implication of the Wnt/β-catenin pathway. *Biochem J.* 2017;474(22):3733-3746.

37. Xu Z, Zhang Y, Xu M, et al. Demethylation and overexpression of CSF2 are involved in immune response, chemotherapy resistance, and poor prognosis in colorectal cancer. *Onco Targets Ther.* 2019;12:11255-11269. doi:10.2147/OTT.S216829.

38. Lee YY, Wu WJ, Huang CN, et al. CSF2 Overexpression is associated with STAT5 phosphorylation and poor prognosis in patients with urothelial carcinoma. *J Cancer.* 2016;7(6): 711-721.

39. Eissmann MF, Dijkstra C, Jarnicki A, et al. IL-33-mediated mast cell activation promotes gastric cancer through macrophage mobilization. *Nat Commun.* 2019;10(1):2735.

40. Kadomoto S, Izumi K, Mizokami A. The CCL20-CCR6 axis in cancer progression. *Int J Mol Sci.* 2020;21(15):51-86.

41. Walch-Rückheim B, Mavrova R, Henning M, et al. Stromal fibroblasts induce CCL20 through IL6/C/EBPβ to support the recruitment of Th17 cells during cervical cancer progression. *Cancer Res.* 2015;75(24):5248-5259.

42. Yu Q, Lou XM, He Y. Preferential recruitment of Th17 cells to cervical cancer via CCR6-CCL20 pathway. *PLoS One.* 2015;10(3):e0120855.

43. Li H, Duan N, Zhang Q, Shao Y. IL1A & IL1B genetic polymorphisms are risk factors for thyroid cancer in a Chinese Han population. *Int Immunopharmacol.* 2019;76(6):105869.

44. Song Z, Lin Y, Ye X, et al. Expression of IL-1α and IL-6 is associated with progression and prognosis of human cervical cancer. *Med Sci Monit.* 2016;22:4475-4481. doi:10.12659/msm.898569.

45. Punt S, Houwing-Duistermaat JJ, Schulkens IA, et al. Correlations between immune response and vascularization qRT-PCR gene expression clusters in squamous cervical cancer. *Mol Cancer.* 2015;14(1):71.

46. Muhammad SB, Hassan F, Bhowmik KK, et al. Detection of association of IL1β, IL4R, and IL6 gene polymorphisms with cervical cancer in the Bangladeshi women by tetra-primer ARMS-PCR method. *Int Immunopharmacol.* 2021;90(9):107131.

47. Yan R, Shuai H, Luo X, Wang X, Guan B. The clinical and prognostic value of CXCL8 in cervical carcinoma patients: immunohistochemical analysis. *Biosci Rep.* 2017;37(5):BSR20171021.

48. Ozga AJ, Chow MT, Luster AD. Chemokines and the immune response to cancer. *Immunity.* 2021;54(5):859-874.

49. Kong W, Zhao G, Chen H, et al. Analysis of therapeutic targets and prognostic biomarkers of CXC chemokines in cervical cancer microenvironment. *Cancer Cell Int.* 2021;21(1):399.

50. Ahmadian E, Dizaj SM, Sharifi S, et al. The potential of nanomaterials in theranostics of oral squamous cell carcinoma: recent progress. *TrAC, Trends Anal Chem.* 2019;116:167-176.

51. Eftekharí A, Hasanzadeh M, Sharifi S, Dizaj SM, Khalilov R, Ahmadian E. Bioassay of saliva proteins: the best alternative for conventional methods in non-invasive diagnosis of cancer. *Int J Biol Macromol.* 2019;124:1246-1255. doi:10.1016/j.ijbiomac.2018.11.277.